Innovent Biologics Collaborates with Roche to Develop IBI3009 for SCLC

Shots:

• Innovent & Roche have entered into a collaboration & exclusive license agreement for developing IBI3009 to treat advanced SCLC
• As per the terms, Roche secures exclusive worldwide rights to develop, manufacture & commercialize IBI3009 plus will lead full development after early-stage studies, conducted jointly. Innovent will get $80M upfront, up to $1B development & commercial milestones as well as net-sales-based tiered royalties
• IBI3009, a novel DLL3-targeting ADC, has IND approvals in Australia, China & the US (P-I dosing started in Dec 2024). Designed using Innovent’s TOPO1i platform, it shows strong anti-tumor activity, particularly in chemo-resistant tumors & has a favorable safety profile

Ref: Prnewswire | Image: Roche & Innovent Biologics

Related News:- Innovent Biologics Reports the P-II Trial Data of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com